Prosecution Insights
Last updated: April 19, 2026
Application No. 17/874,054

PHOTOTHERAPY FACE MASK

Non-Final OA §103
Filed
Jul 26, 2022
Examiner
ANJARIA, SHREYA PARAG
Art Unit
3796
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
The Lotus Global Group Inc. Dba Globalmed Technologies Co.
OA Round
3 (Non-Final)
52%
Grant Probability
Moderate
3-4
OA Rounds
3y 2m
To Grant
83%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allow Rate
65 granted / 124 resolved
-17.6% vs TC avg
Strong +30% interview lift
Without
With
+30.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
41 currently pending
Career history
165
Total Applications
across all art units

Statute-Specific Performance

§101
20.9%
-19.1% vs TC avg
§103
43.4%
+3.4% vs TC avg
§102
12.8%
-27.2% vs TC avg
§112
19.3%
-20.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 124 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 07/07/2025 has been entered. Remarks This action is in response to the Remarks filed 07/07/2025. Claims 1-24 are pending. Response to Arguments No arguments have been provided for the interpretation of the limitation “fastening means” in claims 1, 11, and 18 under 35 U.S.C. 112(f). Therefore, this interpretation is maintained. Applicant’s arguments, see pages 6-11 of Remarks filed 07/07/2025, with respect to the previous rejections of claims 1-20 under 35 U.S.C. 103 have been fully considered and are persuasive. Independent claims 1 and 11 have been amended to recite the electronics layer comprises one or more light sources and the skin contacting layer comprises one or more transparent regions coinciding with the light sources. New claims 21-24 have been added. Applicant argues that Kothari in view of Eisenberg does not disclose the claimed limitations. Examiner agrees. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground of rejection is made, as explained in the office action below. New claims 21-24 are addressed in the office action below. Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Such claim limitations are: the “fastening means” in claims 1, 11, and 18. For examination purposes, the fastening means will be understood to be any type of fasteners, as explained in par. [0036] of the instant specification. Because this/these claim limitation(s) is/are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, it/they is/are being interpreted to cover the corresponding structure described in the specification as performing the claimed function, and equivalents thereof. If applicant does not intend to have this/these limitation(s) interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, applicant may: (1) amend the claim limitation(s) to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph (e.g., by reciting sufficient structure to perform the claimed function); or (2) present a sufficient showing that the claim limitation(s) recite(s) sufficient structure to perform the claimed function so as to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-24 are rejected under 35 U.S.C. 103 as being unpatentable over DeBow (US Patent Application Publication 2021/0023387 – of record), further in view of Bhardwaj (US Patent Application Publication 2022/0339462). Regarding claim 1, DeBow discloses a phototherapy mask for phototherapy treatment of a user (e.g. Abstract), comprising: a backing layer made of a flexible material (e.g. Par. [0078]: flexible face mask; Par. [0045]: mask made of flexible material such as silicone); an electronics layer comprising one or more light sources (e.g. Fig. 2: layer 5 with LEDs 4; Pars. [0051]-[0054]: internal circuitry layer 5 can hold the light sources; Par. [0079]: face mask with internal layer that includes the light sources); a skin-contacting layer comprising one or more transparent regions coinciding with the one or more light sources (e.g. Par. [0048]: the layers 2, 2A that faces the patient is clear to allow the light to pass through; Par. [0079]: face mask contains all of the layer previously described); and fastening means (e.g. Par. [0057]: belt used to hold the mask against the body; Par. [0080]: describing Figs. 13A, B that depict belts; Figs. 13A, B: belts that can be used); wherein: the phototherapy mask is adapted to fold about a face of the user in a first plane and shaped to releasably fasten about a head of the user using the fastening means (e.g. Fig. 12: face mask bent around face of a user in multiple planes to fit around the face and also the neck and chin; Par. [0079]: “The apparatus is meant to be placed on face 162 and secured into place with hook and loop trough rings (e.g., rings 8) attached or embedded into the mask 140.”; Par. [0078]: slits 148 and 150 provided in the facemask to help fold the mask into place around a face of a user; Par. [0080]: describing Figs. 13A, B that depict belts; Figs. 13A, B: belts that can be used); the phototherapy mask includes at least one facial treatment region adapted to fold in a second plane relative to the first plane (e.g. Fig. 12: face mask bent around face of a user in multiple planes to fit around the face and also the neck and chin; Par. [0079]: “The apparatus is meant to be placed on face 162 and secured into place with hook and loop trough rings (e.g., rings 8) attached or embedded into the mask 140.”; Par. [0078]: slits 148 and 150 provided in the facemask to help fold the mask into place around a face of a user); and the phototherapy mask contains an aperture configured to match the user’s nose and mouth (e.g. Pars. [0078]-[0079]: face mask contains opening 146 for nose and mouth of the user). However, DeBow fails to specifically disclose wherein the phototherapy mask comprises at least three apertures configured to match the user's eyes, nose, and mouth. Bhardwaj, in a similar field of endeavor, is directed towards a phototherapy face mask. Bhardwaj discloses wherein the phototherapy face mask comprises at least three apertures configured to match the user's eyes, nose, and mouth (e.g. Fig. 1: openings 104 for the eyes, nose, and mouth; Figs. 2, 3, 5, 6: openings 104 are not labeled but can be seen; Par. [0054]: face mask has openings for the eyes, nose, and mouth to allow the user to see and breathe during the light therapy). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to modify the invention of DeBow to include the apertures as taught by Bhardwaj to allow the user to see and breathe during the therapy (e.g. Bhardwaj, par. [0054]). Regarding claim 11, DeBow discloses a phototherapy mask for phototherapy treatment of a user (e.g. Abstract), comprising: a backing layer made of a flexible material (e.g. Par. [0078]: flexible face mask; Par. [0045]: mask made of flexible material such as silicone); an electronics layer comprising one or more light sources (e.g. Fig. 2: layer 5 with LEDs 4; Pars. [0051]-[0054]: internal circuitry layer 5 can hold the light sources; Par. [0079]: face mask with internal layer that includes the light sources); a skin-contacting layer comprising one or more transparent regions coinciding with the one or more light sources (e.g. Par. [0048]: the layers 2, 2A that faces the patient is clear to allow the light to pass through; Par. [0079]: face mask contains all of the layer previously described); and fastening means configured to releasably fasten the phototherapy mask about a head of the user (e.g. Par. [0057]: belt used to hold the mask against the body; Par. [0080]: describing Figs. 13A, B that depict belts; Figs. 13A, B: belts that can be used); wherein the phototherapy mask contains an aperture configured to match the user’s nose and mouth (e.g. Pars. [0078]-[0079]: face mask contains opening 146 for nose and mouth of the user). However, DeBow fails to specifically disclose wherein the phototherapy mask comprises at least three apertures configured to match the user's eyes, nose, and mouth. Bhardwaj, in a similar field of endeavor, is directed towards a phototherapy face mask. Bhardwaj discloses wherein the phototherapy face mask comprises at least three apertures configured to match the user's eyes, nose, and mouth (e.g. Fig. 1: openings 104 for the eyes, nose, and mouth; Figs. 2, 3, 5, 6: openings 104 are not labeled but can be seen; Par. [0054]: face mask has openings for the eyes, nose, and mouth to allow the user to see and breathe during the light therapy). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to modify the invention of DeBow to include the apertures as taught by Bhardwaj to allow the user to see and breathe during the therapy (e.g. Bhardwaj, par. [0054]). Regarding claims 2 and 13, DeBow further discloses wherein the flexible material comprises silicone (e.g. Par. [0045]). Regarding claims 3 and 14, DeBow further discloses wherein the electronics layer includes a flexible printed circuit board connected to the one or more light sources (e.g. Par. [0039]). Regarding claims 4 and 15, DeBow further discloses wherein the one or more light sources are light-emitting diodes capable of emitting light with at least one wavelength between 300nm and 1200nm (e.g. Par. [0029]: wavelength of 300nm to 1100nm). Regarding claims 5 and 16, DeBow further discloses wherein the at least one wavelength is between 420nm and 1080nm (e.g. Par. [0029]: wavelength of 300nm to 1100nm). Regarding claims 6 and 17, DeBow further discloses wherein the electronics layer further includes an electrical connector configured to electrically connect to a power controller unit that is adapted to provide power to the electronic layer and to control the one or more light sources therein (e.g. Par. [0029]). Regarding claim 7, DeBow further discloses wherein the power controller unit is remote from the phototherapy mask (e.g. Par. [0061]; Fig. 3 showing different power sources). Regarding claim 8, DeBow further discloses wherein the power controller unit is integral to the electronics layer (e.g. Par. [0040]). Regarding claims 9 and 19, DeBow further discloses wherein the at least one facial treatment region is configured to flexibly fold under a user's chin (e.g. Figs. 11A, B: portions 142 for folding under the user’s neck and chin; Fig. 12: face mask with area folded under the user’s chin). Regarding claims 10 and 20, DeBow further discloses wherein the fastening means includes one or more fixing straps and cooperating retainer loops (e.g. Fig. 11B: loops 8 for holding a strap; Par. [0079]). Regarding claim 12, DeBow further discloses wherein the backing layer comprises a flexible material (e.g. Par. [0078]: flexible face mask; Par. [0045]: mask made of flexible material such as silicone). Regarding claim 18, DeBow further discloses the phototherapy mask is adapted to fold about a face of the user in a first plane and shaped to releasably fasten about a head of the user using the fastening means (e.g. Fig. 12: face mask bent around face of a user in multiple planes to fit around the face and also the neck and chin; Par. [0079]: “The apparatus is meant to be placed on face 162 and secured into place with hook and loop trough rings (e.g., rings 8) attached or embedded into the mask 140.”; Par. [0078]: slits 148 and 150 provided in the facemask to help fold the mask into place around a face of a user; Par. [0080]: describing Figs. 13A, B that depict belts; Figs. 13A, B: belts that can be used); and the phototherapy mask includes at least one facial treatment region adapted to fold in a second plane relative to the first plane (e.g. Fig. 12: face mask bent around face of a user in multiple planes to fit around the face and also the neck and chin; Par. [0079]: “The apparatus is meant to be placed on face 162 and secured into place with hook and loop trough rings (e.g., rings 8) attached or embedded into the mask 140.”; Par. [0078]: slits 148 and 150 provided in the facemask to help fold the mask into place around a face of a user). Regarding claims 21 and 23, DeBow further discloses wherein the phototherapy mask is configured for treatment of both the user's face and under the user's chin (e.g. Figs. 11A, B: portions 142 for folding under the user’s neck and chin; Fig. 12: face mask with area folded under the user’s chin); the at least one facial treatment region comprises a first facial treatment region formed on a neck region of the phototherapy mask (e.g. Par. [0078]: neck treatment flaps 142; Fig. 12: face mask with area shown around the neck); the phototherapy mask further comprises a second facial treatment region formed on a facial region of the phototherapy mask (e.g. Pars. [0078]-[0079]: facial treatment mask; Fig. 12: face mask shown on facial region of the user). Regarding claims 22 and 24, DeBow further discloses wherein opposing side ends of the neck region are configured to couple to the facial region to retain the neck region in a folded configuration under the user's chin (e.g. Figs. 11A, B: portions 142 for folding under the user’s neck and chin; Fig. 12: face mask with area folded under the user’s chin). Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Kang et al. (US 2023/0000683 – of record) is directed towards a skin care apparatus. Park (US 2022/0369793 – of record) is directed towards a light emitting mask. Jin et al. (US 2022/0314022 – of record) is directed towards a light emitting skin care device. Lay et al. (US 2021/0370090 – of record) is directed towards a phototherapeutic device. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHREYA P ANJARIA whose telephone number is (571)272-9083. The examiner can normally be reached M-F: 8:00-5:00 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer McDonald can be reached at 571-270-3061. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SHREYA ANJARIA/Examiner, Art Unit 3796 /PAMELA M. BAYS/Primary Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

Jul 26, 2022
Application Filed
May 15, 2023
Response after Non-Final Action
Aug 22, 2024
Non-Final Rejection — §103
Feb 20, 2025
Response Filed
Mar 18, 2025
Final Rejection — §103
Jun 24, 2025
Request for Continued Examination
Jun 26, 2025
Response after Non-Final Action
Jul 07, 2025
Response Filed
Jan 07, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12543992
PACING EFFICACY DETERMINATION USING A REPRESENTATIVE MORPHOLOGY OF EXTERNAL CARDIAC SIGNALS
2y 5m to grant Granted Feb 10, 2026
Patent 12527966
MULTI-TIER PREDICTION OF CARDIAC TACHYARRYTHMIA
2y 5m to grant Granted Jan 20, 2026
Patent 12508076
MULTIPLEXER FOR LASER-DRIVEN INTRAVASCULAR LITHOTRIPSY DEVICE
2y 5m to grant Granted Dec 30, 2025
Patent 12495967
MODULAR WIRELESS PHYSIOLOGICAL PARAMETER SYSTEM
2y 5m to grant Granted Dec 16, 2025
Patent 12490935
ORAL MEASUREMENT DEVICES AND METHODS
2y 5m to grant Granted Dec 09, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
52%
Grant Probability
83%
With Interview (+30.4%)
3y 2m
Median Time to Grant
High
PTA Risk
Based on 124 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month